Advancing transformative therapies for patients with complement-mediated diseases
Complexities of Complement
The complement system is complex and implicated in a large number of autoimmune and inflammatory conditions across hematology, nephrology, neurology, dermatology, ophthalmology and many other disease areas. However, given the complex biology and abundance of proteins involved in the complement system, it has historically been challenging to develop effective and convenient therapies to modulate the complement system.
World Renowned Expertise and LOGIC-based Approach
Founded and advised by world renowned complement biology experts and in collaboration with or op-tier research institutions both in the US and Europe through ongoing sponsored research agreements, Kira Pharmaceuticals is leveraging its proprietary LOGIC platform (Lead identification, Optimization and Attribute Generation, In-vivo Confirmation) to overcome key challenges of developing complement therapeutics and increasing their probability of success in the clinic. We are moving from complexity to clarity to improve the lives of patients.
Kira Pharmaceuticals is pioneering the field, developing a broad pipeline of compelling therapies designed to achieve better, longer acting and targeted immune modulation across a range of complement diseases. With our lead asset entering Phase 2 and nine assets in the pipeline, we are advancing the next generation of complement therapies. These assets are investigational agents and have not yet been approved by any Health Authority, such as the FDA.
About Our Team
Kira’s experienced team includes established drug developers and protein engineers, world-renowned experts in complement biology and leaders from across the pharma and biotech industry. The team is augmented by well-respected academic collaborators at major US and European research institutions alongside an outstanding Scientific Advisory Board with international reputations in complement biology and immunology.